PASSAGE BIO INC's ticker is PASG and the CUSIP is 702712100. A total of 75 filers reported holding PASSAGE BIO INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,602 | -60.8% | 116,416 | -43.9% | 0.00% | – |
| Q2 2023 | $195,285 | +68421.1% | 207,463 | -30.4% | 0.00% | – |
| Q1 2023 | $285 | -57.8% | 298,090 | -39.1% | 0.00% | – |
| Q4 2022 | $676 | -99.9% | 489,501 | -14.3% | 0.00% | – |
| Q3 2022 | $714,000 | -20.0% | 571,242 | +51.0% | 0.00% | -100.0% |
| Q2 2022 | $893,000 | +69.8% | 378,354 | +123.2% | 0.00% | – |
| Q1 2022 | $526,000 | -59.5% | 169,517 | -17.2% | 0.00% | -100.0% |
| Q4 2021 | $1,300,000 | -62.1% | 204,654 | -40.5% | 0.00% | -50.0% |
| Q3 2021 | $3,428,000 | +32.7% | 344,178 | +76.3% | 0.00% | 0.0% |
| Q2 2021 | $2,584,000 | -6.1% | 195,196 | +81.4% | 0.00% | 0.0% |
| Q4 2020 | $2,751,000 | +267.8% | 107,579 | +88.4% | 0.00% | +100.0% |
| Q3 2020 | $748,000 | -71.0% | 57,089 | -65.2% | 0.00% | -83.3% |
| Q1 2020 | $2,581,000 | – | 163,853 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 2,497,922 | $1,648,629 | 2.12% |
| Versant Venture Management, LLC | 4,959,769 | $3,263,528 | 1.74% |
| BML Capital Management, LLC | 2,058,767 | $1,354,669 | 1.24% |
| Acuitas Investments, LLC | 418,161 | $275,150 | 0.16% |
| Orbimed Advisors | 10,124,576 | $6,661,971 | 0.14% |
| Lynx1 Capital Management LP | 190,124 | $125,102 | 0.08% |
| Frazier Life Sciences Management, L.P. | 1,758,219 | $1,156,908 | 0.08% |
| TANG CAPITAL MANAGEMENT LLC | 400,000 | $263,200 | 0.04% |
| Marquette Asset Management, LLC | 86,050 | $56,621 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 506,600 | $333,343 | 0.01% |